BlueRock Therapeutics’ investigational cell therapy lemiretprocel (OpCT-001) for primary photoreceptor diseases granted orphan drug designations by FDA and EMA

U.S. FDA designations are for treating retinitis pigmentosa and cone-rod dystrophy EU EMA designations are for treating syndromic and non-syndromic inherited retinal disorders (IRDs) of the rod-dominant phenotype and non-syndromic IRDs of the cone-dominant phenotype Lemiretprocel (OpCT-001) is an iPSC-derived investigational cell therapy being […] The post BlueRock Therapeutics’ investigational cell therapy lemiretprocel (OpCT-001) for primary photoreceptor diseases granted orphan drug designations by FDA and EMA appeared first on BlueRock Therapeutics LP .